Genus Stock Soars as Full-Year Profit Jumps

Shares of Genus plc (LON:GNS) rose sharply on Thursday after the animal genetics company reported a 24% increase in adjusted pre-tax profit, reflecting strong trading momentum and strategic progress across its business lines.

The stock has rallied more than 24% in early trading, currently at its highest level since March 2023.

For the year ended 30 June 2025, adjusted profit before tax climbed to £74.3 million from £59.8 million, helped by growth in the PIC porcine genetics business and efficiency gains under the ABS Value Acceleration Programme.

Revenue edged up 1% to £672.8 million, while adjusted operating profit including joint ventures rose 19% to £93.1 million.

Statutory pre-tax profit jumped to £28.5 million from £5.5 million, though results were impacted by a £13.3 million decrease in the valuation of biological assets and exceptional expenses.

Cash generation was notably strong, with free cash flow of £40.9 million compared with an outflow in the prior year. Net debt fell to £228.2 million, bringing leverage down to 1.5 times adjusted EBITDA.

Genus also highlighted major regulatory progress, including the landmark U.S. Food and Drug Administration approval for its PRRS-resistant pig gene edit, paving the way for future commercialisation.

In China, the group signed an accelerated joint venture agreement with Beijing Capital Agribusiness, which will provide Genus with a cash payment of $160 million upon completion.

Chief Executive Jorgen Kokke said: “Genus achieved a strong performance in FY25 as we executed our strategic priorities. PIC’s growth was broad-based and the business won significant new royalty customers in China. ABS profitability was substantially improved, primarily through VAP initiatives.”

The board maintained the final dividend at 21.7p per share and reaffirmed that guidance for fiscal 2026 remains in line with market expectations.